Zai Lab Limited (ZLAB) Wednesday reported positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study of Tivdak in patients with cervical cancer. The company's shares were more than 6 percent up in pre-market.
In the study, treatment with Tivdak reduced the risk of death by 45 percent in patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy in the China subpopulation.
Improved overall survival (OS), progression-free survival (PFS) and confirmed objective response rate (ORR) were observed in the China subpopulation treated with Tivdak compared to chemotherapy, consistent with those in the global population.
Zai Lab plans to submit a New Drug Application (NDA) to China's National Medical Products Administration (NMPA) in the first quarter of 2025.
Zai Lab stock had closed at $24.29, down 3.65 percent on Tuesday. It has traded in the range of $13.48 - $36.60 in the last 1 year.
For comments and feedback: editorial@rttnews.com